RE:RE:RE:SOME FACTS....Yes; I've ignored him as well... my first and hopefully my last. I have no problems with people being critical, doing due dilligence and asking hard questions... but to insult a CEO that has taken the company from a market cap of $5m to $105m in 5 years is pure ignorance and I don't have time for it. I've asked Rene multiple times why they don't uplist and he's given serious consideration to it and indicated that it would happen in due course. Good enough for me. My sense is this company is fairly valued. Now going forward, they have a slew of exciting new drugs coming online and I expect we will see EPS of $0.50-0.60 by 2019-2021... which means the stock should double over that timeframe. Unfortunately I'm finding 'investors' want quick and instant returns these days. This company isn't geared for that and I would encourage anyone expecting to make a quick buck on RX to sell their shares and take their speculative dollars elsewhere.